{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:58:04Z","timestamp":1790909884569,"version":"4.1.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anticoagulants are the primary means for the treatment and prevention of venous thromboembolism (VTE), but their clinical standardized application still remains controversial. The present study intends to comprehensively compare the efficacy and safety of various anticoagulants in VTE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medline, Embase, and Cochrane Library from their inception up to August 2023 were searched to compare the efficacy and safety of various anticoagulants in VTE. We extracted data on study settings, baseline characteristics, interventions, and outcomes, applying the intention-to-treat principle. Two researchers assessed study bias using the Cochrane tool, resolving disagreements through discussion or third-party adjudication. Network meta-analyses were performed based on Bayesian generalized linear models, and a frequentist framework with multivariate random effects was used to fit the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In terms of treatment, 58 trials with 119,417 patients proved eligible, while 125 trials with 225,414 patients were included in terms of prevention. All anticoagulants were found to reduce the recurrence or incidence of VTE compared with Placebo, of which high-level evidence indicated that direct thrombin inhibitors (TIs) and novel oral anticoagulants (NOACs) were the two most effective drugs. For treatment, low molecular weight heparin (LMWH), unfractionated heparin (UFH), and vitamin K antagonists (VKAs) significantly increased the risk of major bleeding in comparison to Placebo. For prevention, only UFH (OR 2.0, 95% CI 1.2\u20133.3) and NOACs (OR 1.8, 95% CI 1.2\u20132.6) showed significant increased risks in major bleeding. Additionally, after an exhaustive analysis of NOACs, analysis showed that apixaban (RR 0.5, 95%CI 0.17\u20131.46) had a superior performance in major bleeding compared to rivaroxaban (RR 3.87, 95%CI 1.48\u201310.09).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TIs and NOACs were superior in efficacy with minimal side effects, making them pivotal choices for both prevention and treatment of VTE. Clinical practitioners must carefully weigh drug characteristics, indications, and contraindications to optimize treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=466775<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1519869","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:12:34Z","timestamp":1736313154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Weijie","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e36335","DOI":"10.7759\/cureus.36335","article-title":"Efficacy, safety, and role of antiplatelet drugs in the management of acute coronary syndrome: a comprehensive review of literature","volume":"15","author":"Abubakar","year":"2023","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1160\/TH15-08-0670","article-title":"European Union-28: an annualised cost-of-illness model for venous thromboembolism","volume":"115","author":"Barco","year":"2016","journal-title":"Thrombosis haemostasis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.thromres.2022.05.003","article-title":"Online KidClot education for patients and families initiating warfarin therapy: the eKITE study","volume":"215","author":"Bauman","year":"2022","journal-title":"Thromb. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1160\/TH14-06-0484","article-title":"Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism","volume":"113","author":"Beyer-Westendorf","year":"2015","journal-title":"Thromb. Haemost."},{"key":"B5","doi-asserted-by":"publisher","first-page":"m3900","DOI":"10.1136\/bmj.m3900","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"Bmj"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2036304","DOI":"10.1001\/jamanetworkopen.2020.36304","article-title":"Comparison between non-vitamin K antagonist oral anticoagulants and low-molecular-weight heparin in asian individuals with cancer-associated venous thromboembolism","volume":"4","author":"Chen","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2020.17272","article-title":"Diagnosis and treatment of lower extremity venous thromboembolism: a review","volume":"324","author":"Chopard","year":"2020","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e070022","DOI":"10.1136\/bmj-2022-070022","article-title":"Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis","volume":"378","author":"Eck","year":"2022","journal-title":"Bmj"},{"key":"B11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.phrs.2021.105438","article-title":"Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: a systematic review and a network meta-analysis","author":"Feng","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","article-title":"The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs","volume":"137","author":"Grosse","year":"2016","journal-title":"Thromb. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/cells11203214","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","volume":"11","author":"Heestermans","year":"2022","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","article-title":"Pharmacology of heparin and related drugs: an update","volume":"75","author":"Hogwood","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.7326\/M21-1474","article-title":"Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a nationwide propensity score-weighted study","volume":"174","author":"Ingason","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e074495","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1001\/jama.2022.7325","article-title":"Antithrombotic therapy for venous thromboembolism","volume":"327","author":"Jackson","year":"2022","journal-title":"Jama"},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous thromboembolism","volume":"398","author":"Khan","year":"","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"","journal-title":"Ann. Intern Med."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013422.pub2","article-title":"Treatment of distal deep vein thrombosis","volume":"4","author":"Kirkilesis","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(20)30211-8","article-title":"Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis","volume":"7","author":"Klemen","year":"2020","journal-title":"Lancet Haematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur. Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/00273171.2022.2115965","article-title":"A gentle introduction to bayesian network meta-analysis using an automated R package","volume":"58","author":"Liu","year":"2023","journal-title":"Multivar. Behav. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.dld.2015.01.159","article-title":"Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials","volume":"47","author":"Loffredo","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e007956","DOI":"10.1161\/CIRCEP.121.007956","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"Cd009447","DOI":"10.1002\/14651858.CD009447.pub3","article-title":"Anticoagulation for perioperative thromboprophylaxis in people with cancer","volume":"7","author":"Matar","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2205973","article-title":"Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture","volume":"388","author":"O'Toole","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.mayocp.2020.10.041","article-title":"Direct oral anticoagulants compared with dalteparin for treatment of cancer-associated thrombosis: a living, interactive systematic review and network meta-analysis","volume":"97","author":"Riaz","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1055\/s-0040-1712913","article-title":"Venous thromboembolic diseases: diagnosis, management and thrombophilia testing: observations on NICE guideline [NG158]","volume":"120","author":"Schulman","year":"2020","journal-title":"Thromb. Haemost."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/dj4010005","article-title":"New direct oral anticoagulants (DOAC) and their use today","volume":"4","author":"Schwarb","year":"2016","journal-title":"Dent. J. (Basel)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/cvr\/cvaa044","article-title":"Variations in incidence of venous thromboembolism in low-middle-and high-income countries","volume":"117","author":"Siegal","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"100613","DOI":"10.1016\/j.blre.2019.100613","article-title":"From unfractionated heparin to pentasaccharide: paradigm of rigorous science growing in the understanding of the in vivo thrombin generation","volume":"39","author":"Spadarella","year":"2020","journal-title":"Blood Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"B39","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1001\/jama.2018.14346","article-title":"Venous thromboembolism: advances in diagnosis and treatment","volume":"320","author":"Tritschler","year":"2018","journal-title":"Jama"},{"key":"B41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/sysbio\/syz028","article-title":"An annealed sequential Monte Carlo method for bayesian phylogenetics","volume":"69","author":"Wang","year":"2020","journal-title":"Syst. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0140-6736(15)60806-6","article-title":"Estimate of the global volume of surgery in 2012: an assessment supporting improved health outcomes","volume":"385","author":"Weiser","year":"2015","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jama.2014.65","article-title":"Treatment of venous thromboembolism","volume":"311","author":"Wells","year":"2014","journal-title":"Jama"},{"key":"B44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin. Pharmacokinet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1519869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:12:38Z","timestamp":1736313158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1519869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":44,"alternative-id":["10.3389\/fphar.2024.1519869"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1519869","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1519869"}}